MA27317A1 - Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie - Google Patents

Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie

Info

Publication number
MA27317A1
MA27317A1 MA28033A MA28033A MA27317A1 MA 27317 A1 MA27317 A1 MA 27317A1 MA 28033 A MA28033 A MA 28033A MA 28033 A MA28033 A MA 28033A MA 27317 A1 MA27317 A1 MA 27317A1
Authority
MA
Morocco
Prior art keywords
diabetes
dyslipidemia
obesity
beta
treatment
Prior art date
Application number
MA28033A
Other languages
English (en)
Inventor
Steven H Olson
James M Balkovec
Yuping Zhu
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA27317A1 publication Critical patent/MA27317A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INHIBITEURS DE LA 11-BETA-HYDROXYSTEROiDE DEHYDROGENASE 1 UTILES POUR LE TRAITEMENT DU DIABETE, DE L'OBESITE ET DE LA DYSLIPIDEMIE Les composés ayant la Formule I, comprenant les sels pharmaceutiquement acceptables, hydrates et solvates de ceux-là : sont des inhibiteurs sélectifs de l'enzyme 11(beta)-HSD1. Les composés sont utiles pour le traitement du diabète, tel que le diabète non insulinodèpendant (DNID), l'hyperglycémie, l'obésité, la résistance à l'insuline, la dyslipidémie, l'hyperlipidémie, l'hypertension, le Syndrome X, et les autres symptômes liés au DNID.
MA28033A 2002-06-10 2005-01-05 Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie MA27317A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38738502P 2002-06-10 2002-06-10

Publications (1)

Publication Number Publication Date
MA27317A1 true MA27317A1 (fr) 2005-05-02

Family

ID=29736306

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28033A MA27317A1 (fr) 2002-06-10 2005-01-05 Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie

Country Status (29)

Country Link
US (2) US6730690B2 (fr)
EP (1) EP1532122B1 (fr)
JP (1) JP4405384B2 (fr)
KR (1) KR20050008805A (fr)
CN (2) CN1312137C (fr)
AR (1) AR040241A1 (fr)
AT (1) ATE537155T1 (fr)
AU (2) AU2003251410B2 (fr)
BR (1) BR0311137A (fr)
CA (1) CA2488592C (fr)
EC (1) ECSP045482A (fr)
ES (1) ES2377200T3 (fr)
HK (1) HK1081946A1 (fr)
HR (1) HRP20041180A2 (fr)
IL (1) IL165257A0 (fr)
IS (1) IS7519A (fr)
JO (1) JO2315B1 (fr)
MA (1) MA27317A1 (fr)
MX (1) MXPA04012381A (fr)
MY (1) MY134664A (fr)
NO (1) NO20050102L (fr)
NZ (1) NZ536188A (fr)
PE (1) PE20040726A1 (fr)
PL (1) PL373372A1 (fr)
RU (1) RU2319703C2 (fr)
TW (1) TWI324153B (fr)
UA (1) UA81417C2 (fr)
WO (2) WO2003104208A1 (fr)
ZA (1) ZA200408772B (fr)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148987A1 (en) * 2001-12-21 2003-08-07 Morris David J. Selective 11beta-HSD inhibitors and methods of use thereof
US20060148725A1 (en) * 2001-12-21 2006-07-06 The Miriam Hospital Selective 11beta HSD inhibitors and methods of use thereof
DE60317631T2 (de) 2002-02-01 2008-09-25 Merck & Co., Inc. 11-beta-hydroxysteroid-dehydrogenase-1-hemmer zur behandlung von diabetes, adipositas und dyslipidämie
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
ATE374766T1 (de) 2003-01-14 2007-10-15 Arena Pharm Inc 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
CA2524165A1 (fr) * 2003-04-29 2004-11-11 The Miriam Hospital Inhibiteurs 11.beta.-hsd de testosterone selectifs et methodes d'utilisations
WO2004110375A2 (fr) * 2003-06-06 2004-12-23 Merck & Co., Inc. Polytherapie permettant de traiter le diabete
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
CA2539741A1 (fr) 2003-09-22 2005-03-31 Bionetworks Gmbh Prevention et traitement de la perte osseuse induite par inflammation et/ou immuno-mediee
US7683059B2 (en) 2003-10-28 2010-03-23 Amgen Inc. Triazole compounds and uses related thereto
US20050137209A1 (en) * 2003-12-18 2005-06-23 Agy Therapeutics, Inc. Treatment of neurologic disorders with inhibitors of 11beta-HSD1
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
CA2553345C (fr) * 2004-01-26 2011-11-15 Merck & Co., Inc. Nouvelles formes cristallines d'un inhibiteur de la 11-beta-hydroxysteroide dehydrogenase de type 1
US7354938B2 (en) 2004-03-23 2008-04-08 Amgen Inc. Pyrazole compounds and uses related thereto
US20080255216A1 (en) * 2004-03-29 2008-10-16 Aster Susan D Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1
US20050261302A1 (en) * 2004-04-29 2005-11-24 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
WO2005108360A1 (fr) 2004-05-07 2005-11-17 Janssen Pharmaceutica N.V. Utilisation de derives de pyrrolidin-2-one et de piperidin-2-one comme inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase
CN1980889B (zh) * 2004-05-07 2010-11-10 詹森药业有限公司 11-β羟基类固醇脱氢酶抑制剂的金刚烷基吡咯烷-2-酮衍生物
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
WO2005121132A1 (fr) * 2004-06-11 2005-12-22 Shionogi & Co., Ltd. Composé hétérocyclique fondu ayant un effet anti-vhc
US20060025445A1 (en) * 2004-08-02 2006-02-02 Xiang Jason S 11-Beta HSD1 inhibitors
GB0418877D0 (en) * 2004-08-24 2004-09-29 Univ Edinburgh Heart
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
CN101039908B (zh) 2004-08-30 2010-06-23 詹森药业有限公司 作为11-β羟甾类脱氢酶抑制剂的三环内酰胺衍生物
EA012263B1 (ru) 2004-08-30 2009-08-28 Янссен Фармацевтика Н.В. Производные n-2-адамантанил-2-феноксиацетамида в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
CN101014578B (zh) * 2004-09-16 2011-01-19 安斯泰来制药有限公司 三唑衍生物或其盐
JP5140577B2 (ja) 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド ヒドロキシステロイドデヒドロゲナーゼ阻害剤
ES2369389T3 (es) 2005-04-05 2011-11-30 F. Hoffmann-La Roche Ag 1h-pirazol-4-carboxamidas, su preparación y su empleo como inhibidores de 11-beta- hidroxiesteroide dehidrogenasa.
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US8952176B2 (en) * 2005-06-07 2015-02-10 Shionogi & Co., Ltd. Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) * 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
MY147393A (en) 2005-09-14 2012-11-30 Takeda Pharmaceutical Administration of dipeptidyl peptidase inhibitors
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
RU2302066C1 (ru) * 2005-09-22 2007-06-27 Научный центр волоконной оптики при Институте общей физики им. А.М. Прохорова Российской академии наук Волоконный световод для оптического усиления излучения на длине волны в диапазоне 1000-1700 нм, способы его изготовления и волоконный лазер
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
CN101312951A (zh) * 2005-11-21 2008-11-26 盐野义制药株式会社 具有Ⅰ型11β羟基类固醇脱氢酶抑制活性的杂环化合物
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007082808A2 (fr) 2006-01-18 2007-07-26 F. Hoffmann-La Roche Ag Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
WO2007088895A1 (fr) * 2006-01-31 2007-08-09 Mochida Pharmaceutical Co., Ltd. Derive de 3-arylamino-1,2,4-triazole
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
RU2008140940A (ru) 2006-03-16 2010-04-27 Астеллас Фарма Инк. (Jp) Производное триазола или его соль
WO2007112347A1 (fr) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EA016853B1 (ru) 2006-08-24 2012-08-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Замещенные ациланилиды и их применение
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
EP2083831B1 (fr) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AR064623A1 (es) * 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
PL2163543T3 (pl) 2007-05-18 2015-06-30 Shionogi & Co Heterocykliczna pochodna zawierająca azot o aktywności hamującej dehydrogenazę 11-beta-hydroksysteroidową typu I
US8222417B2 (en) 2007-06-27 2012-07-17 Taisho Pharmaceutical Co., Ltd Compound having 11β-HSD1 inhibitory activity
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2009126624A1 (fr) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Composés triazolos utiles en tant qu'inhibiteurs de dgat1
US8394823B2 (en) * 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors
MX2011000179A (es) 2008-07-03 2011-04-05 Astellas Pharma Inc Derivado de triazol o su sal.
WO2010003624A2 (fr) 2008-07-09 2010-01-14 Sanofi-Aventis Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
PE20110852A1 (es) 2008-10-30 2011-11-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
EP2358200A4 (fr) 2008-11-17 2012-05-16 Merck Sharp & Dohme Amines bicycliques substituées pour le traitement du diabète
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
JP2012517479A (ja) * 2009-02-12 2012-08-02 エグゼリクシス， インコーポレイテッド 糖尿病および肥満の処置においてｔｇｒ５アゴニストとして使用するためのトリアゾールおよびイミダゾール誘導体
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011019538A1 (fr) 2009-08-13 2011-02-17 Merck Sharp & Dohme Corp. Composés cyclopropyle substitués, compositions contenant de tels composés et procédés de traitement
EP2470552B1 (fr) 2009-08-26 2013-11-13 Sanofi Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, produits pharmaceutiques comprenant ces composés et leur utilisation
EP2473047B1 (fr) 2009-09-02 2014-08-13 Merck Sharp & Dohme Corp. Aminotétrahydropyranes utilisés comme inhibiteurs de la dipeptyl peptidase-iv pour traiter ou prévenir le diabète
WO2011071957A1 (fr) 2009-12-07 2011-06-16 Sea Lane Biotechnologies, Llc Conjugués comprenant un échafaudage de substituts d'anticorps présentant des propriétés pharmacocinétiques améliorées
TW201120027A (en) * 2009-12-11 2011-06-16 Exelixis Inc TGR5 agonists
EP2538783B1 (fr) 2010-02-22 2016-06-01 Merck Sharp & Dohme Corp. Aminotétrahydrothiopyranes substitués et dérivés de ceux-ci utilisés en tant qu'inhibiteurs de la dipeptidylpeptidase-iv dans le cadre du traitement du diabète
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8980929B2 (en) 2010-05-21 2015-03-17 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2605658B1 (fr) 2010-08-18 2016-03-23 Merck Sharp & Dohme Corp. Composés spiroxazolidinone
UA112418C2 (uk) 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
CA2812061A1 (fr) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulateurs du recepteur gpr119 et traitement des troubles qui lui sont lies
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
EP2683698B1 (fr) 2011-03-08 2017-10-04 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120057A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683701B1 (fr) 2011-03-08 2014-12-24 Sanofi Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
CA2831334A1 (fr) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Composes a cyclopropyle substitue, compositions contenant de tels composes et methodes de traitement
JP5901025B2 (ja) 2011-04-19 2016-04-06 第一三共株式会社 テトラヒドロチアゼピン誘導体
US20140088124A1 (en) 2011-06-02 2014-03-27 Robert J. DeVita Imidazole derivatives
WO2012173917A1 (fr) 2011-06-16 2012-12-20 Merck Sharp & Dohme Corp. Composés cyclopropylés substitués, compositions contenant de tels composés et procédés de traitement
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP2760855B1 (fr) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Composés de cyclopropyle substitués, compositions contenant ces composés ainsi que leur utilisation pour le traitement du diabète de type 2
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2013062838A1 (fr) 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Composés de pipéridinyle substitués utilisés comme agonistes du récepteur gpr119
WO2013068328A1 (fr) 2011-11-07 2013-05-16 Intervet International B.V. Composés d'acide bicyclo[2.2.2]octan-1-ylcarboxylique comme inhibiteurs de la dgat-1
WO2013068439A1 (fr) 2011-11-09 2013-05-16 Intervet International B.V. Composés 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazépine comme inhibiteurs de dgat1
US9018224B2 (en) 2011-11-15 2015-04-28 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
EP2814485A4 (fr) 2012-02-17 2015-08-26 Merck Sharp & Dohme Inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prévention du diabète
CN104411710A (zh) 2012-04-16 2015-03-11 卡内克制药公司 作为ptp-1b抑制剂前体的稠合的芳族膦酸酯衍生物
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
EP3733170A1 (fr) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. Procédé de traitement de cancers du sein positifs aux récepteurs des androgène (ar) à l'aide d'un modulateur sélectif des récepteurs androgènes (sarm)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
EP2874622A4 (fr) 2012-07-23 2015-12-30 Merck Sharp & Dohme Traitement du diabète par administration d'inhibiteurs de dipeptidyl peptidase-iv
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
US9453038B2 (en) 2012-12-17 2016-09-27 Merck Sharp & Dohme Corp. Glucokinase activator compounds, compositions containing such compounds, and methods of treatment
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2015089809A1 (fr) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Composés hétéroaryles substitués antidiabétiques
WO2015112465A1 (fr) 2014-01-24 2015-07-30 Merck Sharp & Dohme Corp. Dérivés d'isoquinoline utilisés comme inhibiteurs de mgat2
WO2015176267A1 (fr) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2015189330A1 (fr) * 2014-06-12 2015-12-17 Universite De Lille 2 Droit Et Sante Dérivés d'imidazole ou de 1,2,4-triazol et leur utilisation
WO2016022742A1 (fr) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
WO2016022448A1 (fr) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
EP3177285B1 (fr) 2014-08-08 2020-09-23 Merck Sharp & Dohme Corp. Composés antidiabétiques bicycliques à fusion [5,6]
CA3093383A1 (fr) 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonistes des recepteurs du glucagon et du glp-1
TN2017000113A1 (en) 2014-10-31 2018-07-04 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
CN107405332A (zh) 2015-01-06 2017-11-28 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
US10245264B2 (en) 2015-05-27 2019-04-02 Merck Sharp & Dohme Corp. Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
EP3310782B1 (fr) 2015-05-28 2021-12-01 Merck Sharp & Dohme Corp. Dérivés d'imidazo-pyrazinyle utiles à titre d'activateurs de guanylate cyclase solubles
CA3002551A1 (fr) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Sel cristallin de l-arginine de (r)(7-(4-cyclopentyle-3-(trifluoromethyle)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acide acetique(compose 1) aux fins d'utilisation contre les troubles associes au recepteur s1p1
US10800826B2 (en) 2015-10-05 2020-10-13 Merck Sharp & Dohme Corp. Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
WO2017107052A1 (fr) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Activateurs solubles de guanylate cyclase
EP3235813A1 (fr) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Dérivés aza-tétra-cycliques
WO2017197555A1 (fr) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Dérivés de pyrazine fusionnés utiles en tant que stimulateurs de la guanylate cyclase soluble
WO2017201683A1 (fr) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Composés de tétrahydroisoquinoline substitués utiles à titre d'agonistes de gpr120
EP3496715B1 (fr) 2016-08-15 2021-11-03 Merck Sharp & Dohme Corp. Composés utiles pour modifier les taux d'acides biliaires pour le traitement du diabète et de maladies cardiométaboliques.
WO2018034918A1 (fr) 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Composés utiles pour modifier les taux d'acides biliaires pour le traitement du diabète et de maladies cardiométaboliques.
US11008313B2 (en) 2016-09-20 2021-05-18 Merck Sharp & Dohme Corp. Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders
US10947222B2 (en) 2016-11-18 2021-03-16 Merck Sharp & Dohme Corp. Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
WO2018107415A1 (fr) 2016-12-15 2018-06-21 Merck Sharp & Dohme Corp. Composés d'hydroxy isoxazole utiles en tant qu'agonistes de gpr120
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
US20220177465A1 (en) 2019-04-04 2022-06-09 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
EP4010314B1 (fr) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle
WO2021041770A1 (fr) 2019-08-30 2021-03-04 Merck Sharp & Dohme Corp. Composés antagonistes du pcsk9
EP3842449A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes d'oléfine agrafés du glucagon et récepteurs glp-1
EP3842060A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes lactames agrafés des récepteurs du glucagon et du glp-1
EP3842061A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes triazoles agrafés des récepteurs du glucagon et du glp-1
US20230174521A1 (en) 2020-05-18 2023-06-08 Merck Sharp & Dohme Llc Novel diacylglyceride o-acyltransferase 2 inhibitors
TW202227417A (zh) 2020-08-18 2022-07-16 美商默沙東藥廠 雙環庚烷吡咯啶之食慾素受體促效劑
KR102445638B1 (ko) 2020-09-03 2022-09-20 충남대학교산학협력단 11 알파 하이드록시프로게스테론을 포함하는 당뇨병 예방 또는 치료용 조성물
AU2021356589A1 (en) 2020-10-08 2023-05-25 Merck Sharp & Dohme Llc Preparation of benzimidazolone derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
MX2024002146A (es) 2021-08-19 2024-03-08 Merck Sharp & Dohme Llc Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9.
CN116003279B (zh) * 2022-06-13 2024-05-28 苏州大学 一种绿色的n-甲基酰胺化合物的制备方法
WO2023244554A1 (fr) 2022-06-15 2023-12-21 Merck Sharp & Dohme Llc Peptides cycliques pour piéger l'interleukine-1 bêta
WO2024118858A1 (fr) 2022-12-02 2024-06-06 Merck Sharp & Dohme Llc Préparation de dérivés d'azole fusionnés utilisés en tant que nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2160899A (en) 1997-12-11 1999-06-28 Janssen Pharmaceutica N.V. Retinoic acid mimetic anilides
US20030073850A1 (en) 1998-08-07 2003-04-17 Altenbach Robert J. 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
US6503935B1 (en) 1998-08-07 2003-01-07 Abbott Laboratories Imidazoles and related compounds as α1A agonists
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
JPWO2003004497A1 (ja) 2001-07-05 2004-10-28 住友製薬株式会社 新規複素環化合物
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors

Also Published As

Publication number Publication date
CA2488592C (fr) 2010-08-10
ATE537155T1 (de) 2011-12-15
US20040106664A1 (en) 2004-06-03
WO2003104207A2 (fr) 2003-12-18
JP2005532357A (ja) 2005-10-27
AU2003251410A1 (en) 2003-12-22
WO2003104207A3 (fr) 2004-03-25
RU2004139063A (ru) 2005-06-27
MXPA04012381A (es) 2005-04-19
AU2003243420A1 (en) 2003-12-22
HRP20041180A2 (en) 2005-08-31
ES2377200T3 (es) 2012-03-23
AU2003251410B2 (en) 2009-05-21
HK1081946A1 (en) 2006-05-26
PE20040726A1 (es) 2004-10-23
ZA200408772B (en) 2005-11-18
AR040241A1 (es) 2005-03-23
ECSP045482A (es) 2005-01-28
TWI324153B (en) 2010-05-01
US6730690B2 (en) 2004-05-04
IS7519A (is) 2004-10-29
WO2003104208A1 (fr) 2003-12-18
BR0311137A (pt) 2005-02-22
US7179802B2 (en) 2007-02-20
CN1312137C (zh) 2007-04-25
PL373372A1 (en) 2005-08-22
TW200410947A (en) 2004-07-01
MY134664A (en) 2007-12-31
NZ536188A (en) 2006-11-30
JP4405384B2 (ja) 2010-01-27
IL165257A0 (en) 2005-12-18
NO20050102L (no) 2005-02-10
JO2315B1 (en) 2005-09-12
CA2488592A1 (fr) 2003-12-18
AU2003243420A8 (en) 2003-12-22
US20040048912A1 (en) 2004-03-11
KR20050008805A (ko) 2005-01-21
CN1990474A (zh) 2007-07-04
RU2319703C2 (ru) 2008-03-20
EP1532122B1 (fr) 2011-12-14
UA81417C2 (en) 2008-01-10
CN1659151A (zh) 2005-08-24
EP1532122A1 (fr) 2005-05-25

Similar Documents

Publication Publication Date Title
MA27317A1 (fr) Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie
MA27579A1 (fr) Derives de triazole comme inhibiteurs de la 11-beta-hydroxysteroide-deshydrogenase 1
MA30201B1 (fr) Derives triazoliques comme inhibiteurs de la 11-beta-hydroxysteroide dehydrogenase-1
BR0210167A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado com proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição e para abaixar a glicose no sangue, e, uso de um composto
ATE394413T1 (de) Peptidylketone als inhibitoren der dpiv
BR0009864A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto
ATE476425T1 (de) Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1
DK0687251T3 (da) 1,3-dihydroindol-2-on-derivater, der er substitueret i 3-stillingen med en nitrogengruppe, til anvendelse som vasopressin- og/eller ocytocin-agonister og/eller -antagonister
ATE427926T1 (de) Cycloalkylaminderivate
ATE472531T1 (de) Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
MA30476B1 (fr) Derives de type cyclohexylpyrazole-lactame comme inhibiteurs de la 11-beta-hydroxysteroïde deshydrogenase de type 1
ATE329901T1 (de) 3-substituierte oxindolderivate als beta-3- agonisten
TW200505919A (en) DPP-IV inhibitors
ATE419848T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
ATE401073T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
WO2007127763A3 (fr) Inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase 1
WO2007127688A3 (fr) Inhibiteurs de 1-beta-hydroxystéroïde déshydrogenase 1
TNSN06359A1 (fr) Aryl-ou heteroaryl-amides substitues en position ortho
PT1960352E (pt) Derivados de 2-adamantilureia como inibidores seletivos de 11â-hsd1
TW200504063A (en) DPP-IV inhibitors
ATE399546T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
BRPI0407180A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto
WO2003048130A3 (fr) Agonistes du recepteur active de proliferation du peroxisome
BR0315683A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento e/ou prevenção de condições mediadas por receptores nucleares e para o tratamento e/ou prevenção do diabete do tipo i, diabete do tipo ii, tolerância à glicose prejudicada, resistência à insulina ou obesidade
BRPI0506793A (pt) métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5